Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212250 | 0.89 | HPGD (0.60) | TSHRHPGDMEN1KMT2ALMNA | |
| SCHEMBL4409746 | 0.86 | HPGD (0.66) | L3MBTL1TSHRHPGDMEN1KMT2A | |
| SCHEMBL13798395 | 0.86 | HPGD (0.70) | L3MBTL1TSHRHPGDMEN1KMT2A | |
| SCHEMBL7581128 | 0.85 | POLB (0.74) | L3MBTL1TSHRRECQLHPGDKDM4E | |
| SCHEMBL4402800 | 0.85 | HPGD (0.73) | L3MBTL1TSHRHPGDMEN1KMT2A | |
| SCHEMBL14212254 | 0.85 | HPGD (0.73) | L3MBTL1TSHRHPGDMEN1KMT2A | |
| SCHEMBL10720509 | 0.84 | L3MBTL1 (0.71) | L3MBTL1TSHRRECQLHPGDKDM4E | |
| SCHEMBL12305548 | 0.84 | HPGD (0.68) | TSHRHPGDMEN1KMT2ALMNA | |
| SCHEMBL2627051 | 0.83 | HSP90AA1 (0.61) | L3MBTL1HSP90AA1HSP90AB1TSHRHPGD | |
| SCHEMBL12203375 | 0.82 | HPGD (0.67) | HPGDMEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210101872-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-04-08 | — | — | US | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | Epizyme, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | L3MBTL1 982/4885HSP90AA1 4440/4885HSP90AB1 4187/4885 |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | L3MBTL1 4614/4885HSP90AA1 3595/4885HSP90AB1 2255/4885 |
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | L3MBTL1 3791/4885HSP90AA1 4626/4885HSP90AB1 4516/4885 |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | NCOR1, NR3C1, NR3C2 | L3MBTL1 3827/4885HSP90AA1 3566/4885HSP90AB1 2913/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | L3MBTL1 1306/4885HSP90AA1 4331/4885HSP90AB1 4170/4885 |
| US-10391089-B2 | PRMT5 inhibitors and uses therof | PRMT5, PRMT1, PRMT6 | L3MBTL1 651/4885HSP90AA1 4282/4885HSP90AB1 3998/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | L3MBTL1 106/4885HSP90AA1 1537/4885HSP90AB1 1808/4885 |
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | L3MBTL1 1306/4885HSP90AA1 4331/4885HSP90AB1 4170/4885 |
| US-20190083482-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | L3MBTL1 982/4885HSP90AA1 4440/4885HSP90AB1 4187/4885 |
| US-20210101872-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | L3MBTL1 106/4885HSP90AA1 1537/4885HSP90AB1 1808/4885 |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | L3MBTL1 1928/4885HSP90AA1 3387/4885HSP90AB1 2808/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | L3MBTL1 1886/4885HSP90AA1 962/4885HSP90AB1 852/4885 |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | L3MBTL1 982/4885HSP90AA1 4440/4885HSP90AB1 4187/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | L3MBTL1 1042/4885HSP90AA1 4459/4885HSP90AB1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.